CLINICAL TRIALS AND OBSERVATIONS Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
نویسندگان
چکیده
1Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2BioBridges, Boston, MA; 3McMaster University Medical Center, Hamilton, ON; 4University of California Los Angeles (UCLA) Medical Center; 5Greenebaum Cancer Center, University of Maryland, Baltimore; 6Medical Oncology, St Bartholomew’s Hospital and Cancer Research, London, United Kingdom; 7Clinical Hematology, Centre Hospitalier Schaffner, Lens, France; 8Rocky Mountain Cancer Center, Denver, CO; 9Rush University Medical Center, Chicago, IL; and 10Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, and rituximab (FCR) for previously treated patients with CLL and identify patients who benefit most from this therapy. We explore efficacy of FCR in...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenström macroglobulinemia
1Service d’Hématologie, Hôpital Schaffner, Lens, France; 2Laboratoire d’Hématologie, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France; 3Service d’Anatomo-pathologie, Hôpital Schaffner, Lens, France; 4 CHU Clermont-Ferrand, Hôpital Estaing, Service d’Anatomo-pathologie, Clermont Ferrand, France; 5Laboratoire d’Hématologie, Hôpital Schaffner, Lens, France; 6 Laboratoire de Biochimie...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden
A role for genetic factors in the etiology of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) is implicated based on prior findings from multiply affected families and small case-control and cohort studies. We identified 2144 LPL/WM patients (1539 WM [72%] and 605 LPL [28%]) diagnosed in Sweden, 8279 population-based matched controls, and linkable first-degree relatives of pat...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Thalidomide and rituximab in Waldenstrom macroglobulinemia
Steven P. Treon,1,2 Jacob D. Soumerai,1 Andrew R. Branagan,1 Zachary R. Hunter,1 Christopher J. Patterson,1 Leukothea Ioakimidis,1 Frederick M. Briccetti,3 Mark Pasmantier,4 Harvey Zimbler,5 Robert B. Cooper,6 Maria Moore,7 John Hill II,8 Alan Rauch,9 Lawrence Garbo,9 Luis Chu,10 Cynthia Chua,11 Stephen H. Nantel,12 David R. Lovett,13 Hans Boedeker,14 Henry Sonneborn,15 John Howard,16 Paul Must...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum -2 microglobulin ( 2M) > 4 mg/L. Sixty patients were enrolled; median age was 59 years (range,...
متن کامل